CervoMed Inc. (CRVO)
USD 2.0
(3.09%)
USD 2.0
(3.09%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.44 Million | -2.57 Million | -14.5 Million | -13.55 Million | -9.85 Million | -10.77 Million |
| Net Income | -2.17 Million | -5.8 Million | -24.09 Million | -14.18 Million | -11.79 Million | -18.36 Million |
| Depreciation & Amortization | - | - | 93.41 Thousand | 103.16 Thousand | 97.91 Thousand | 110.37 Thousand |
| Deferred income taxes | - | - | -443.89 Thousand | -1.67 Million | 332.88 Thousand | -437.28 Thousand |
| Stock-based compensation | 407.63 Thousand | 333.83 Thousand | 897.26 Thousand | 736.11 Thousand | - | - |
| Change in working capital | -261.35 Thousand | 379.93 Thousand | 356.37 Thousand | 1.46 Million | 994.44 Thousand | -276.93 Thousand |
| Other non-cash items | -4.66 Million | 2.77 Million | 9.16 Million | -8147.00 | 143.92 Thousand | 8.69 Million |
| Investing Cash Flow | - | -12.23 Million | 4000.00 | - | - | - |
| Investments in PPE | -3.00 | - | - | - | - | - |
| Acquisitions | - | - | 4000.00 | - | - | - |
| Investment purchases | - | -37.98 Million | - | - | - | - |
| Sales/Maturities of investments | - | 25.75 Million | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 11.14 Million | - | 33.29 Million | 17.89 Million | 16.04 Million | 9.86 Million |
| Debt repayment | - | - | -6 Million | - | - | -550 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 810 Thousand | - | 33.29 Million | 17.89 Million | 16.04 Million | 10.41 Million |
| Other Financing Activities | 10.33 Million | - | - | -982.32 Thousand | -162.82 Thousand | - |
| Accounts receivables | -915.4 Thousand | - | - | - | - | - |
| Accounts payables | 565.16 Thousand | 79.15 Thousand | 605.37 Thousand | 950.6 Thousand | 567.66 Thousand | -275.83 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 88.88 Thousand | 300.78 Thousand | -248.99 Thousand | 518.16 Thousand | 426.77 Thousand | -1102.00 |
| Cash at beginning of period | 4.09 Million | 37.31 Million | 18.51 Million | 14.17 Million | 7.99 Million | 8.89 Million |
| Cash at end of period | 7.79 Million | 4.09 Million | 37.31 Million | 18.51 Million | 14.17 Million | 7.99 Million |
| Capital Expenditure | -3.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 3.69 Million | -33.21 Million | 18.79 Million | 4.33 Million | 6.18 Million | -905.29 Thousand |
| Free Cash Flow | -7.44 Million | -2.57 Million | -14.5 Million | -13.55 Million | -9.85 Million | -10.77 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.31 Million | -2.51 Million | -2.36 Million | -2.17 Million | 2.15 Million | -2.11 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 578.58 Thousand | 218.21 Thousand | 164.97 Thousand | 407.63 Thousand | 60.62 Thousand | 110.79 Thousand |
| Change in working capital | -125.11 Thousand | 872.44 Thousand | -341.02 Thousand | -261.35 Thousand | 1.61 Million | -588.49 Thousand |
| Other non-cash items | -53.41 Thousand | -466.78 Thousand | -17.52 Thousand | -4.66 Million | -2.39 Million | 716.51 Thousand |
| Investing Cash Flow | -40.57 Million | - | - | - | -12.5 Million | 3 Million |
| Investments in PPE | 5.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -40.57 Million | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | -12.5 Million | 3 Million |
| Other Investing Activities | -40.57 Million | - | - | - | - | - |
| Financing Cash Flow | 46.41 Million | - | -93.37 Thousand | 11.14 Million | 11.24 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 46.41 Million | - | - | 810 Thousand | 810 Thousand | - |
| Other Financing Activities | 46.41 Million | - | -93.37 Thousand | 10.33 Million | 10.43 Million | - |
| Accounts receivables | - | 915.4 Thousand | - | -915.4 Thousand | - | - |
| Accounts payables | 293.78 Thousand | -230.4 Thousand | 182.49 Thousand | 565.16 Thousand | 1.33 Million | -660.95 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -418.89 Thousand | 187.44 Thousand | 391.88 Thousand | 88.88 Thousand | -419.34 Thousand | 72.46 Thousand |
| Cash at beginning of period | 6.36 Million | 7.79 Million | 10.42 Million | 4.09 Million | 14.99 Million | 14.64 Million |
| Cash at end of period | 10 Million | 6.36 Million | 7.79 Million | 7.79 Million | 10.42 Million | 14.99 Million |
| Capital Expenditure | 5.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 3.64 Million | -1.42 Million | -2.63 Million | 3.69 Million | -4.57 Million | 353.96 Thousand |
| Free Cash Flow | -2.2 Million | -1.42 Million | -2.53 Million | -7.44 Million | 2.7 Million | -2.64 Million |
CRGX
HXL
SESN
ALQWA
300102
PTOS